Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP262 (MRGPRX2 Antagonist) in Atopic Dermatitis (EASE)
NCT06144424Phase 2Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of EP262 in atopic dermatitis (AD), sponsored by Escient Pharmaceuticals. Started Oct 2023; status: completed.
02
Drugs
EP262
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06144424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144424.